Polypharmacy of heart failure: Creating a rational pharmacotherapeutic protocol

Cardiology Clinics

Volumn 19, Issue 4, 2001, Pages 583-596

  Wilson Tang, W H ^a   Francis, Gary S ^a,b,c  

^a Department of Cardiology ^*  (United States)

^b Heart Rhythm Service   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUMETANIDE; CANDESARTAN; CAPTOPRIL; CARDIOVASCULAR AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; FUROSEMIDE; HYDRALAZINE; LISINOPRIL; LOSARTAN; METOLAZONE; METOPROLOL; NEUROHORMONE; POTASSIUM CHLORIDE; RAMIPRIL; SPIRONOLACTONE; TORASEMIDE; UNINDEXED DRUG; VALSARTAN;

CLINICAL TRIAL; COMORBIDITY; DIAGNOSTIC ACCURACY; HEART FAILURE; HUMAN; PATIENT COMPLIANCE; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; TREATMENT PLANNING;

EID: 0034766820     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8651(05)70245-9     Document Type: Article

References (97)

1. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials
2. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
3. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction: Pharmacological approaches
4. Angioedema due to angiotensin-converting enzyme inhibitors
5. Adverse effects of the angiotensin-converting enzyme inhibitors
6. Antiplatelet agents and survival: A cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial
7. β-blocker titration failure is independent of severity of heart failure
8. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
9. Evidence-based medicine and ACE inhibition
10. Spironolactone use in heart failure: Spiraling out of control?
11. Diuretic therapy
12. Congestive heart failure: Fifty years of progress
13. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA Investigators
14. Advanced congestive heart failure: What do patients want?
15. The cardiac insufficiency bisoprolol study II (CIBISII): A randomised trial
16. Changes in mortality from heart failure: United States, 1980- 1995
17. Are symptoms the most important target for therapy in chronic heart failure?
18. Valsartan in heart failure trial (Val-HeFT)
19. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative study
20. Cardiac remodeling-concepts and clinical implications: A consensus paper from an international forum on cardiac remodeling
21. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
22. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure: US Carvedilol Heart Failure Study Group
23. Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
24. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure
25. Risk stratification in chronic heart failure
26. The role of digitalis in the treatment of heart failure
27. The effect of digoxin on mortality and morbidity in patients with heart failure
28. Application of cine nuclear magnetic resonance imaging for sequential evaluation of response to angiotensin-converting enzyme inhibitor therapy in dilated cardiomyopathy
29. Combination diuretic therapy in severe congestive heart failure
30. A trial of the β-blocker bucindolol in patients with advanced chronic heart failure
31. Prevention of nitrate tolerance with concomitant administration of hydralazine
32. The role of organic nitrates in the treatment of heart failure
33. Potentiation of furosemide by metolazone in refractory edema
34. Organisation of the care of patients with heart failure
35. Long-term ACEinhibitor therapy in patients with heart failure or leftventricular dysfunction: A systematic overview of data from individual patient
36. Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction
37. Changing the remodeling process in heart failure: Basic mechanisms and laboratory results
38. Overview of randomized trials of angiotensin converting-enzyme inhibitors on mortality and morbidity in patients with heart failure
39. Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
40. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: Results of the SOLVD echocardiography substudy
41. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade
42. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
43. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics
44. Safety and efficacy of β-blockade in patients with chronic congestive heart failure awaiting transplantation
45. Diuretic treatment and diuretic resistance in heart failure
46. New and emerging pharmacologic strategies in the management of chronic heart failure
47. Efficacy and safety of carvedilol in patients with chronic heart failure receiving concomitant amiodarone therapy: Australia/New Zealand Heart Failure Research Collaborative Group
48. Aspirin and mortality in patients treated with angiotensinconverting enzyme inhibitors: A cohort study of 11,575 patients with coronary artery disease
49. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure
50. Impact of concurrent amiodarone treatment on the tolerability and efficacy of carvedilol in patients with chronic heart failure
51. Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure
52. Cough and angiotensin II receptor antagonists: Cause or confounding?
53. Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management
54. Safety and costs of initiating angiotensin converting enzyme inhibitors for heart failure in primary care: Analysis of individual patient data from studies of left ventricular dysfunction
55. Failure to practice evidence-based medicine: Why do physicians not treat patients with heart failure with angiotensin-converting enzyme inhibitors?
56. Effect of Metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
57. Combination therapy with carvedilol and amiodarone in patients with severe heart failure
58. Does aspirin interfere with the therapeutic efficacy of angiotensin-converting enzyme inhibitors in hypertension or congestive heart failure?
59. Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors
60. Clinical outcome with enalapril in symptomatic chronic heart failure: A dose comparison
61. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: Subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)
62. Economic impact of heart failure in the United States: Time for a different approach
63. Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention
64. Effect of carvedilol on survival in severe chronic heart failure
65. Prospective randomized amlodipine survival evaluation II (PRAISE II) trial
66. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
67. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure
68. Ventricular remodeling and its prevention in the treatment of heart failure
69. Enhancing cardiac protection after myocardial infarction: Rationale for newer clinical trials of angiotensin receptor blockers
70. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial
71. Clinical consequences of angiotensin converting-enzyme inhibitor withdrawal in chronic heart failure: A doubleblind placebo-controlled study of quinapril
72. Comprehensive multidisciplinary programs for the management of of chronic heart failure
73. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin-converting enzyme inhibitor: Implications for therapy
74. The anti-ischemic potential of angiotensinconverting enzyme inhibition: Insights from the heart outcomes prevention evaluation trial
75. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial: The Losartan Heart Failure Survival Study ELITE II
76. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)
77. The Effect of spironolactone on morbidity and mortality in patients with severe heart failure
78. From kinetics to dynamics: Are there differences between ACE inhibitors?
79. Diuretics in cardiovascular therapy: The new clinicopharmacological bases that matter
80. Class effects and evidence-based medicine
81. Epidemiology of heart failure and ventricular dysfunction
82. Haemodynamic impact of diuretic therapy in chronic heart failure
83. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
84. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
85. Preference for treatment outcomes in patients with heart failure: Symptoms versus survival
86. Steering Committee and Membership of the Advisory Council to improve Outcomes Nationwide in Heart Failure: Consensus recommendations for the management of chronic heart failure
87. Healthcare costs of patients with heart failure treated with torasemide or furosemide
88. Aldosterone escape during angiotensinconverting enzyme inhibitor therapy in chronic heart failure
89. The inotropic and hemodynamic effects of intravenous milrinone when reflex adrenergic stimulation is suppressed by β-adrenergic blockade
90. Potential risk of β-blockade withdrawal in congestive heart failure due to abrupt autonomic changes
91. Beyond drug therapy: Nonpharmacologic care of the patient with advanced heart failure
92. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance
93. Combination drug therapy in patients with heart failure: Tenets of rational polypharmacy
94. Long-term β-blockade in dilated cardiomyopathy: Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol
95. Effect of diuresis on the performance of the failing left ventricle in man
96. Patterns of medication use in patients with heart failure: A report from the Registry of Studies of Left Ventricular Dysfunction (SOLVD)
97. Over 20 years' experience of β-blockade in heart failure